lacosamide/intas f.c.tab 200mg/tab
intas third party sales 2005 sl, spain world trade center, edifici est, 6th floor/6a planta, 08039 barcelona +34 93 301 73 51 - lacosamide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 200mg/tab - lacosamide 200mg - lacosamide
lacosamide/intas f.c.tab 50mg/tab
intas third party sales 2005 sl, spain world trade center, edifici est, 6th floor/6a planta, 08039 barcelona +34 93 301 73 51 - lacosamide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 50mg/tab - lacosamide 50mg - lacosamide
ambrisentan accord 10mg film coated tablets
accord healthcare s.l.u (0000009808) moll de barcelona, edifici est s/n, planta 6, barcelona, 08039 - ambrisentan - film coated tablets - 10mg - ambrisentan (0177036941) 10mg
ambrisentan accord 5mg film coated tablets
accord healthcare s.l.u (0000009808) moll de barcelona, edifici est s/n, planta 6, barcelona, 08039 - ambrisentan - film coated tablets - 5mg - ambrisentan (0177036941) 5mg
fibryga 50ml solution for injection
octapharma (ip) sprl (0000010636) alle de la recherche 65, anderlecht, bruxelles - capitale, 1070 - factor i (fibrinogen) - solution for injection - 50ml - factor i (fibrinogen) (0009001325) 1g
abiraterone accord
accord healthcare s.l.u. - οξική απιρατερόνη - Νεοπλάσματα του προστάτη - Ενδοκρινική θεραπεία - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - Χοίροι - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.